Treatment programmes and care for stomach cancer
Stomach cancer, a common malignant tumour in the digestive system, has the highest morbidity and mortality rates in the country. Treatment for stomach cancer usually includes procedures such as surgery, chemotherapy, treatment, targeting and immunisation, depending on the stage of cancer and the overall health status of the patient.
The whole body treatment for stomach cancer is divided into two scenarios: for restricted stomach cancer, first-span surgery or post-operative chemotherapy; and for partially terminal, re-emergence or transferable stomach cancer, palliative care, including leachate, whole-body treatment and/or optimal support treatment, is recommended. The full-body treatment programme should be selected on the basis of the patient ‘ s state of physical capacity (PS), internal-synthesis and toxic effects. For patients in good physical condition, the combination of full-body chemotherapy against the HER-2 target (the transcontinental gland cancer expressed in Her2) can be considered as a combination. In the case of patients with poor physical capacity, priority should be given to improvement options and appropriate adjustments to dosage and drug programmes. In the case of patients suffering from syndrome, a combination of their overall state of health and resilience needs to be considered. For example, for patients with severe cardiovascular diseases, the use of certain drugs that may increase cardiovascular risk may need to be avoided.
Because of the complexity of the choice, dose and toxicity treatment of anti-cancer drugs, an experienced medical team is required to develop the best delivery plan and to adapt it to the specific circumstances of the patient. Common combinations of drugs include fluorine, Osharipine, Capitabin, Dositas, etc., which can be used individually or in combination, with different combinations of drugs and doses selected for intravenous or oral use, depending on the circumstances. Treatment for certain drugs should be interrupted or suspended in the case of serious heart problems (e.g. heart failure, loss of left heart function) or serious infusion-related reactions.
The treatment of stomach cancer drugs, especially chemotherapy and target-oriented treatment, can have multiple side effects. For example, chemotherapy can cause nausea, vomiting, bone marrow inhibition (e.g., increased risk of infection as a result of white cell reduction), signs of digestive tracts (e.g., abdominal swelling, indigestion). Targeting drugs such as Apatini may cause hypertension, protein urine, hand and foot skin reactions, etc. Patients should therefore closely monitor their health, report promptly any symptoms of discomfort and treat them as prescribed by the doctor.
During full-body drug treatment, patients are required to measure vital signs, weight and blood cytometers at least once a week, and to perform biochemical tests, such as hepato-renal abnormalities, and timely intervention and stop medications when white-cell and plate counts are below normal. Prophyxia, anti-acid and anti-laxatives are also used, as appropriate. For patients with pain symptoms, appropriate painkillers and non-pharmacological treatments, such as physiotherapy, relaxation training, etc., are chosen.
The diet requires a small amount of food, which is easy to digest, high proteins and high fibres. (b) Diversifying diets with more food with vitamins and micronutrients in order to ensure nutritional balance and, where necessary, to consider oral or intestine high nutrition to ensure adequate calorie intake.
Maintaining a positive and optimistic mentality and diverting attention through listening to music and watching television to reduce the psychological stress of drug use. Since chemotherapy may reduce immunity, measures are needed to prevent infection, such as maintaining personal hygiene and avoiding exposure to pathogens. (d) Provide rehabilitation guidance, including appropriate physical exercise, respiratory exercises, etc., to improve physical and quality of life. Depending on the patient ‘ s condition, the medical treatment and guidance can be considered in support of treatment and rehabilitation.
In addition, the integrated treatment of stomach cancer requires multidisciplinary team collaboration, with multidisciplinary integrated treatment models involving specialists from various disciplines, such as gastrointestinal surgery, digestive internal medicine, oncology, endoscopy centres, and discharge therapy. This model not only facilitates the development of individualized precision treatment programmes, but also allows for the selection of the most appropriate treatments and the management of side effects according to the specific circumstances of the patient. Through the collaboration of multidisciplinary teams, it is possible to establish a rational process of treatment for stomach cancer, introduce new technologies and methods and improve and improve existing treatments, thus improving their efficiency and quality.
In addition to routine treatment, the involvement of people with stomach cancer in clinical research is of great significance and may have a positive impact on treatment outcomes. First, our country has a unique advantage in clinical research on stomach cancer, including a large population base, a wealth of case resources and a high rate of progressive stomach cancer, all of which contribute to real-world research. Such large-scale real-world data can provide broader evidence of applicability and effectiveness for clinical treatment. The involvement of people with stomach cancer in clinical research not only contributes to the advancement of medicine, but also directly improves the treatment effectiveness and prognosis of patients. Through the above information, people with stomach cancer can better understand what needs to be done during full-body treatment and work closely with the medical team to consider individual differences, side effects management and multidisciplinary integrated treatment strategies in order to achieve optimal treatment and quality of life.
NCCN Clinical Practice Guide: Stomach Cancer. National Comprehensive Council Network (NCCN) [2022-01-10].
2024 edition of CACA Guidelines for the Integrated Treatment of Stomach Cancer
Stomach cancer
